{
  "question_stem": {
    "en": "A 62-year-old woman is admitted to the hospital for a living-donor kidney transplant. She has a history of end-stage kidney disease due to diabetic nephropathy and has been undergoing hemodialysis for the last 2 years. The transplant surgery is performed without complication, and the patient demonstrates good urine output afterward. To help prevent rejection, she is given a medication that inhibits the conversion of inosine monophosphate to guanosine monophosphate primarily in lymphocytes, causing reduced proliferation of activated lymphocytes.",
    "zh": "一名62岁女性因活体供肾移植入院。患者有因糖尿病肾病引起的终末期肾病的病史，并且在过去2年中一直在接受血液透析。移植手术顺利完成，术后患者表现出良好的尿量。为了帮助预防排斥反应，她被给予一种药物，该药物主要抑制淋巴细胞中肌苷一磷酸转化为鸟苷一磷酸的过程，从而导致活化淋巴细胞增殖减少。"
  },
  "question": {
    "en": "Which of the following medications is most likely being used in this patient?",
    "zh": "以下哪种药物最有可能用于该患者？"
  },
  "options": {
    "A": {
      "en": "Azathioprine",
      "zh": "硫唑嘌呤"
    },
    "B": {
      "en": "Mycophenolate",
      "zh": "霉酚酸酯"
    },
    "C": {
      "en": "Prednisone",
      "zh": "泼尼松"
    },
    "D": {
      "en": "Sirolimus",
      "zh": "西罗莫司"
    },
    "E": {
      "en": "Tacrolimus",
      "zh": "他克莫司"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "Mycophenolate {{exhibit_1}} is an immunosuppression drug used to prevent organ transplant rejection. It functions via the inhibition of inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme in the de novo purine synthesis pathway. The utility of mycophenolate as an immunosuppressant is aided by its relatively specific suppression of lymphocyte proliferation compared with other hematopoietic cell lines (eg, neutrophils, erythrocytes). This relative lymphocyte specificity is driven by 2 factors:\n\n*   Activated lymphocytes have a nearly absent purine salvage pathway and therefore are mostly dependent on de novo purine synthesis. Other hematopoietic cell lines have a more robust purine salvage pathway and can better compensate for inhibition of the de novo pathway.\n*   There are 2 subtypes of the IMPDH enzyme: Lymphocytes primarily contain type 2 IMPDH, whereas other cell lines contain a greater proportion of type 1. Mycophenolate binds to and inhibits type 2 IMPDH with a higher affinity than type 1.\n\nCommon adverse effects of mycophenolate include lymphopenia and gastrointestinal disturbances (eg, diarrhea).\n\n(Choice A) Azathioprine produces active metabolites that inhibit an enzyme in the de novo purine synthesis pathway and also act as false nucleotides that incorporate into and disrupt DNA and RNA. Both the de novo and salvage purine synthesis pathways are disrupted, resulting in relatively nonspecific hematopoietic suppression.\n\n(Choice C) Prednisone and other glucocorticoids inhibit NF-κB to decrease the transcription of IL-2 and many other cytokines. These drugs have wide-ranging effects that suppress the function of all leukocyte cell lines.\n\n(Choice D) Sirolimus inhibits the mammalian target of rapamycin (mTOR) to interrupt IL-2 signal transduction and provide relatively specific lymphocyte suppression.\n\n(Choice E) Tacrolimus and cyclosporine inhibit calcineurin to block transcription of IL-2. These drugs provide relatively specific lymphocyte suppression and are the mainstay of therapy for preventing organ transplant rejection.\n\nEducational objective:\nMycophenolate is an immunosuppression drug that inhibits inosine 5'-monophosphate dehydrogenase in the de novo purine synthesis pathway. It provides relatively specific suppression of lymphocyte proliferation, largely because activated lymphocytes lack an established purine salvage pathway that is present in other hematopoietic cell lines.\n\n{{exhibit_2}} {{exhibit_3}}",
    "zh": "霉酚酸酯{{exhibit_1}}是一种用于预防器官移植排斥反应的免疫抑制剂。它通过抑制肌苷-5'-磷酸脱氢酶 (IMPDH) 发挥作用，该酶是新生嘌呤合成途径中的一种酶。与其他造血细胞系（如中性粒细胞、红细胞）相比，霉酚酸酯作为免疫抑制剂的效用在于其对淋巴细胞增殖的相对特异性抑制。这种相对的淋巴细胞特异性是由以下两个因素驱动的：\n\n*   活化淋巴细胞几乎没有嘌呤补救途径，因此主要依赖于新生嘌呤合成。其他造血细胞系具有更强大的嘌呤补救途径，并且可以更好地补偿新生途径的抑制。\n*   IMPDH 酶有两种亚型：淋巴细胞主要包含 2 型 IMPDH，而其他细胞系包含更大比例的 1 型。霉酚酸酯与 2 型 IMPDH 结合并抑制其，亲和力高于 1 型。\n\n霉酚酸酯的常见不良反应包括淋巴细胞减少症和胃肠道紊乱（例如，腹泻）。\n\n（选项 A）硫唑嘌呤产生活性代谢物，抑制新生嘌呤合成途径中的一种酶，并且还充当错误核苷酸，这些核苷酸掺入并破坏 DNA 和 RNA。新生和补救嘌呤合成途径均被破坏，导致相对非特异性的造血抑制。\n\n（选项 C）泼尼松和其他糖皮质激素抑制 NF-κB，以减少 IL-2 和许多其他细胞因子的转录。这些药物具有广泛的影响，可抑制所有白细胞细胞系的功能。\n\n（选项 D）西罗莫司抑制雷帕霉素的哺乳动物靶标 (mTOR)，从而中断 IL-2 信号转导，并提供相对特异性的淋巴细胞抑制。\n\n（选项 E）他克莫司和环孢素抑制钙调神经磷酸酶，以阻断 IL-2 的转录。这些药物提供相对特异性的淋巴细胞抑制，是预防器官移植排斥反应的主要治疗方法。\n\n教育目标：\n霉酚酸酯是一种免疫抑制剂，可抑制新生嘌呤合成途径中的肌苷-5'-磷酸脱氢酶。它提供相对特异性的淋巴细胞增殖抑制，这主要是因为活化的淋巴细胞缺乏其他造血细胞系中存在的已建立的嘌呤补救途径。\n\n{{exhibit_2}} {{exhibit_3}}"
  },
  "summary": {
    "en": "This question tests knowledge of immunosuppressant medications used in organ transplant rejection prevention, specifically the mechanism of action and lymphocyte specificity of mycophenolate. It also requires understanding of purine synthesis pathways in lymphocytes. \n\nThe best approach is to recall the mechanism of action of each immunosuppressant drug and consider which one would selectively target lymphocytes. Mycophenolate's inhibition of IMPDH in the de novo purine synthesis pathway, coupled with lymphocytes' dependence on this pathway, makes it the most likely choice.",
    "zh": "此问题考察了关于用于器官移植排斥反应预防的免疫抑制药物的知识，特别是霉酚酸酯的作用机制和淋巴细胞特异性。它还需要理解淋巴细胞中的嘌呤合成途径。\n\n最好的方法是回忆每种免疫抑制剂的作用机制，并考虑哪一种会选择性地靶向淋巴细胞。霉酚酸酯对新生嘌呤合成途径中 IMPDH 的抑制，加上淋巴细胞对该途径的依赖性，使其成为最有可能的选择。"
  },
  "tags": "Kidney transplant; Immunosuppression; Mycophenolate; Purine synthesis; Lymphocytes; IMPDH; Organ rejection; Pharmacology",
  "category": "Immunology",
  "question_id": "18706",
  "has_exhibits": true,
  "exhibit_count": 3,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Immunology 23\\18706",
  "extracted_at": "2025-11-05T14:42:08.117439",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:01:10.731867",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}